WEST PHARMACEUTICAL SERVICES INC — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
West Pharmaceutical reported Q2 2026 net sales of $872.3M (+13.8% YoY, +12.7% organic), with diluted EPS of $2.15 (+18.1%) and adjusted EPS of $2.37 (+28.8%). The company raised full-year 2026 net sales guidance to $3.345B–$3.380B (from $3.295B–$3.350B) and adjusted EPS guidance to $8.85–$9.05 (from $8.40–$8.75). Growth driven by High-Value Product Components (49% of sales, +18.4% organic), HVP Delivery Devices (+29.2% organic), and strong Biologics momentum (+29.2% organic). Share repurchases totaled $454.3M for 1.8M shares at $258.03/share in H1 2026.
Why this rating
Strong organic growth (12.7%), margin expansion, and raised guidance demonstrate robust execution in large high-margin segments (HVP 49% of sales). Guidance raise reflects confidence but headwinds (cyber incident, West Vantage weakness, SmartDose divestiture) temper trajectory-altering impact for $15.7B company.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.